210 related articles for article (PubMed ID: 8649558)
1. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study.
Confavreux C; Saddier P; Grimaud J; Moreau T; Adeleine P; Aimard G
Neurology; 1996 Jun; 46(6):1607-12. PubMed ID: 8649558
[TBL] [Abstract][Full Text] [Related]
2. Azathioprine for multiple sclerosis.
Casetta I; Iuliano G; Filippini G
Cochrane Database Syst Rev; 2007 Oct; 2007(4):CD003982. PubMed ID: 17943809
[TBL] [Abstract][Full Text] [Related]
3. Risk of cancer among Finnish multiple sclerosis patients.
Hongell K; Kurki S; Sumelahti ML; Soilu-Hänninen M
Mult Scler Relat Disord; 2019 Oct; 35():221-227. PubMed ID: 31404761
[TBL] [Abstract][Full Text] [Related]
4. Azathioprine for multiple sclerosis.
Casetta I; Iuliano G; Filippini G
J Neurol Neurosurg Psychiatry; 2009 Feb; 80(2):131-2; discussion 132. PubMed ID: 19151017
[TBL] [Abstract][Full Text] [Related]
5. [Prolonged treatment of multiple sclerosis with average doses of azathioprine. An evaluation of 15 years' experience].
Lhermitte F; Marteau R; Roullet E; de Saxcé H; Loridan M
Rev Neurol (Paris); 1984; 140(10):553-8. PubMed ID: 6438761
[TBL] [Abstract][Full Text] [Related]
6. Secondary myelodysplastic syndrome following long-term treatment with azathioprine in patients with multiple sclerosis.
Putzki N; Knipp S; Ramczykowski T; Vago S; Germing U; Diener HC; Limmroth V
Mult Scler; 2006 Jun; 12(3):363-6. PubMed ID: 16764353
[TBL] [Abstract][Full Text] [Related]
7. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis.
Lebrun C; Debouverie M; Vermersch P; Clavelou P; Rumbach L; de Seze J; Wiertlevski S; Defer G; Gout O; Berthier F; Danzon A
Mult Scler; 2008 Apr; 14(3):399-405. PubMed ID: 18420778
[TBL] [Abstract][Full Text] [Related]
8. Long term azathioprine fails to prevent onset of multiple sclerosis: report of two cases.
Constantinescu CS; Whiteley A; Blumhardt LD
Mult Scler; 2000 Oct; 6(5):362-3. PubMed ID: 11064448
[TBL] [Abstract][Full Text] [Related]
9. The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study.
D'Amico E; Leone C; Graziano G; Amato MP; Bergamaschi R; Cavalla P; Coniglio G; Di Battista G; Ferrò MT; Granella F; Granieri E; Lugaresi A; Lus G; Millefiorini E; Pozzilli C; Tedeschi G; Zappia M; Comi G; Trojano M; Lepore V; Patti F
PLoS One; 2016; 11(6):e0157721. PubMed ID: 27348606
[TBL] [Abstract][Full Text] [Related]
10. Risk of non-melanoma skin cancer in myasthenia patients treated with azathioprine.
Pedersen EG; Pottegård A; Hallas J; Friis S; Hansen K; Jensen PE; Gaist D
Eur J Neurol; 2014 Mar; 21(3):454-8. PubMed ID: 24330255
[TBL] [Abstract][Full Text] [Related]
11. Cancer risk for multiple sclerosis patients treated with azathioprine and disease-modifying therapies: an Italian observational study.
La Mantia L; Benedetti MD; Sant M; d'Arma A; Di Tella S; Lillini R; Mendozzi L; Marangi A; Turatti M; Caputo D; Rovaris M
Neurol Sci; 2021 Dec; 42(12):5157-5163. PubMed ID: 33791892
[TBL] [Abstract][Full Text] [Related]
12. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study.
Armstrong RG; West J; Card TR
Am J Gastroenterol; 2010 Jul; 105(7):1604-9. PubMed ID: 20104215
[TBL] [Abstract][Full Text] [Related]
13. The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study.
Bernatsky S; Joseph L; Boivin JF; Gordon C; Urowitz M; Gladman D; Fortin PR; Ginzler E; Bae SC; Barr S; Edworthy S; Isenberg D; Rahman A; Petri M; Alarcón GS; Aranow C; Dooley MA; Rajan R; Sénécal JL; Zummer M; Manzi S; Ramsey-Goldman R; Clarke AE
Ann Rheum Dis; 2008 Jan; 67(1):74-9. PubMed ID: 17545189
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety of azathioprine therapy in multiple sclerosis.
Amato MP; Pracucci G; Ponziani G; Siracusa G; Fratiglioni L; Amaducci L
Neurology; 1993 Apr; 43(4):831-3. PubMed ID: 8469348
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging.
Massacesi L; Parigi A; Barilaro A; Repice AM; Pellicanò G; Konze A; Siracusa G; Taiuti R; Amaducci L
Arch Neurol; 2005 Dec; 62(12):1843-7. PubMed ID: 16344342
[TBL] [Abstract][Full Text] [Related]
16. Risk of malignancy in myasthenia gravis patients exposed to azathioprine therapy for a median period of 3 years.
Rawoot A; Little F; Heckmann JM
S Afr Med J; 2006 Dec; 96(12):1249-51. PubMed ID: 17252153
[No Abstract] [Full Text] [Related]
17. Risk of cancer with immunosuppressants compared to immunomodulators in multiple sclerosis: A nested case-control study within the French nationwide claims database.
Bosco-Lévy P; Boutmy E; Guiard E; Foch C; Lassalle R; Favary C; Sabidó M; Blin P
Pharmacoepidemiol Drug Saf; 2023 Dec; 32(12):1421-1430. PubMed ID: 37555380
[TBL] [Abstract][Full Text] [Related]
18. Use of azathioprine for non-thymoma myasthenia and risk of cancer: a nationwide case-control study in Denmark.
Pedersen EG; Pottegård A; Hallas J; Friis S; Hansen K; Jensen PE; Gaist D
Eur J Neurol; 2013 Jun; 20(6):942-8. PubMed ID: 23448676
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive treatments in MS--side effects from azathioprine.
Craner MJ; Zajicek JP
J Neurol; 2001 Jul; 248(7):625-6. PubMed ID: 11518009
[No Abstract] [Full Text] [Related]
20. Long-term outcome of patients with Crohn's disease who respond to azathioprine.
Camus M; Seksik P; Bourrier A; Nion-Larmurier I; Sokol H; Baumer P; Beaugerie L; Cosnes J
Clin Gastroenterol Hepatol; 2013 Apr; 11(4):389-94. PubMed ID: 23142207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
